GS-8873 (TFA)

• Description :

  GS-8873 TFA is the TFA salt form of GS-8873 (HY-145713) . GS-8873 TFA is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC50 of 4 nM. GS-8873 TFA exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 TFA causes neurofunctional deficits in rats and cynomolgus monkeys[1][2].

• Product Name Alternative :

  HBV-IN-19 (TFA)

• UNSPSC :

  12352005

• Target :

  HBV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/gs-8873-tfa.html

• Solubility :

  10 mM in DMSO

• Smiles :

  OC(C(F)(F)F)=O.COCC1=C(OCCCOC)C=C([C@]2([H])N(C(C)(CC2)C)N3C4=CC(C(C(O)=O)=C3)=O)C4=C1

• Molecular Formula :

  C26H31F3N2O8

• Molecular Weight :

  556.53

• References & Citations :

  [1]Evangelos Aktoudianakis, et al. Compounds for the treatment of hepatitis b virus infection.WO2018144605A1.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2241575-60-8]